SCHEMBL5281032

SCHEMBL5281032

O=C(O)CNS(=O)(=O)Cc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 3/20 0.62
MMP13 P45452 3/20 0.62
MMP1 P03956 3/20 0.62
CA1 P00915 2/20 0.62
CA2 P00918 2/20 0.62
MMP2 P08253 1/20 0.62
MMP9 P14780 1/20 0.62
MMP12 P39900 3/20 0.58
GAA P10253 1/20 0.51
MMP7 P09237 1/20 0.51
HPGD P15428 1/20 0.50
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
KMT2A Q03164 1/20 0.47
FAAH O00519 1/20 0.47
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
ELANE P08246 1/20 0.47
PRTN3 P24158 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7200212 0.88 CA2 (0.67) MMP8MMP13MMP1CA1CA2
SCHEMBL2895067 0.85 MMP1 (0.58) MMP8MMP13MMP1CA1CA2
SCHEMBL4170793 0.83 MMP12 (0.82) MMP8MMP13MMP1MMP12GAA
SCHEMBL5112333 0.83 MMP13 (0.57) MMP8MMP13MMP1CA1CA2
SCHEMBL5320468 0.83 MMP1 (0.56) MMP8MMP13MMP1CA1CA2
SCHEMBL5286331 0.82 MMP1 (0.55) MMP8MMP13MMP1CA1CA2
SCHEMBL3187084 0.81 CA1 (0.58) MMP8MMP13MMP1CA1CA2
SCHEMBL20657049 0.80 EPHX2 (0.56) MMP8MMP13MMP1CA1CA2
SCHEMBL14798598 0.79 MMP13 (0.47) MMP8MMP13MMP1CA1CA2
SCHEMBL15145818 0.79 ALDH1A1 (0.54) MMP8MMP13MMP1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3287456-B1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) 2020-08-26 EP claimed
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE HORIKOSHI, HIROYOSHI (CA) 2013-06-27 US claimed
EP-2581373-A1 BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE Fujita, Takashi (JP) 2013-04-17 EP claimed
EP-2643295-A1 GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS Chiesi Farmaceutici S.p.A. (IT) 2013-10-02 EP disclosed
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE HORIKOSHI, HIROYOSHI (CA) 2013-06-27 US disclosed
EP-2581373-A1 BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE Fujita, Takashi (JP) 2013-04-17 EP disclosed
WO-2012069275-A1 GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARMACEUTICI S.P.A. (IT) 2012-05-31 WO disclosed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed
US-6541497-B1 Amino acid derivatives of benzoxazin-2-ylaminoalkoxyphenylalkyl compounds ELI LILLY AND COMPANY 2003-04-01 US disclosed
US-6353027-B1 ENANTIOMORPHIC AMINE DERIVATIVES FOR TREATMENT OF DIABETES ELI LILLY AND COMPANY 2002-03-05 US disclosed
US-6194446-B1 NON-INSULIN DEPENDENT DIABETES ELI LILLY AND COMPANY 2001-02-27 US disclosed
EP-1027333-A4 THROMBIN INHIBITORS MERCK & CO INC (US) 2000-11-08 EP disclosed
EP-1027333-A1 THROMBIN INHIBITORS Merck & Co., Inc. (US) 2000-08-16 EP disclosed
WO-1999016750-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 1999-04-08 WO disclosed
US-4885027-A PLANT GROWTH REGULATORS; NONPHYTOTOXIC; PRE- AND POST EMERGENCE CHEVRON RESEARCH COMPANY (US) 1989-12-05 US disclosed
US-4831179-A HERBICIDES CHEVRON RESEARCH COMPANY (US) 1989-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 MMP8 387/4885MMP13 2144/4885MMP1 3485/4885
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE PPARG, PPARA, PPARD MMP8 3662/4885MMP13 3868/4885MMP1 3426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.